Home › Funds › Catalio Capital Management, LP › CRVS

Catalio Capital Management, LP position in CRVS

CORVUS PHARMACEUTICALS I · Health Care

Catalio Capital Management, LP reported holding 1,080,888 shares of CRVS (CORVUS PHARMACEUTICALS I) in its Q2 2026 13F filing — a position valued at US$16.1M, representing 3.03% of its reported portfolio and ranking #14 among its reported holdings. Catalio Capital Management, LP has disclosed CRVS holdings in 2 of the last 2 reported quarters, going back to Q1 2026.

Latest position (Q2 2026)1.08M sh
Reported value held$16.15M
Portfolio Weight3.03%
First reportedQ1 2026
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Catalio Capital Management, LP's CRVS position evolved

Catalio Capital Management, LP first disclosed a stake in CRVS in Q1 2026 at 891,933 shares (US$13.0M). The position peaked in Q2 2026 at 1,080,888 shares, worth US$16.1M. Across 2 filings, Catalio Capital Management, LP increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 1,080,888 shares valued at US$16.1M — an increase of 188,955 shares quarter over quarter..

Quarter by quarter

QuarterSharesValueChange
Q1 2026 891.93K $13.05M New
Q2 2026 1.08M $16.15M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About CRVS and 13F data

CRVS (CORVUS PHARMACEUTICALS I) is a Health Care company. 72 other funds we track also report a position in CRVS — the largest reported positions include ORBIMED ADVISORS LLC (US$107.0M), ADAMS STREET PARTNERS LLC (US$48.9M), Vivo Capital, LLC (US$41.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding CRVS

All CRVS fund holders →

FAQ

How long has Catalio Capital Management, LP held CRVS?

Catalio Capital Management, LP has disclosed CRVS holdings in 2 of the last 2 reported quarters, going back to Q1 2026.

What is Catalio Capital Management, LP's current position in CRVS?

As of Q2 2026, Catalio Capital Management, LP holds 1.08M shares of CRVS (CORVUS PHARMACEUTICALS I), valued at $16.15M, representing 3.03% of its reported portfolio and ranking #14.

Has Catalio Capital Management, LP been buying or selling CRVS?

In the latest 13F filing (Q2 2026), Catalio Capital Management, LP increased its position in CRVS. The position peaked in Q2 2026 at 1.08M shares.

Which other funds hold CRVS?

Other major institutional holders of CRVS include ORBIMED ADVISORS LLC, ADAMS STREET PARTNERS LLC, Vivo Capital, LLC, among 72 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.